Updated recommendations from the Vaccine Committee of the Panamanian Society of Pediatrics on vaccination against Human Papillomavirus (HPV)

Abstract

Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections worldwide and is closely linked to multiple types of cancer, especially cervical cancer (CC), as well as anogenital and oropharyngeal neoplasms. In this editorial, the Vaccine Committee of the Panamanian Society of Pediatrics presents an update of its recommendations on HPV vaccination, based on the latest scientific evidence and with the aim of strengthening good practices in the national context.

The epidemiological situation of CC in Latin America and Panama is reviewed, where it remains one of the leading causes of cancer mortality in women. It highlights the progress made with the incorporation of tetravalent and nonavalent vaccines into the Expanded Program on Immunization, the inclusion of males in the national schedule since 2016, and the consolidation of a two- or three-dose schedule according to age and immunocompetence.

It also highlights the excellent safety profile of these vaccines, their potential co-administration with other immunizations, and international recommendations regarding incomplete schedules. The Committee reiterates the importance of maintaining the same biological product throughout the series, although it recognizes certain flexibilities under WHO and ACIP guidelines.

This document reaffirms the commitment of the Vaccine Committee of the Panamanian Society of Pediatrics to actively promote, continuously update, and support public policies that guarantee equitable access to this essential primary prevention tool.

The epidemiological situation of CCU in Latin America and Panama is reviewed, where it continues to be one of the leading causes of cancer mortality in women. It highlights the progress made with the incorporation of tetravalent and nonavalent vaccines into the Expanded Program on Immunization, the inclusion of males in the national schedule since 2016, and the consolidation of a two- or three-dose schedule based on age and immunocompetence.